Biopharmx Corp (NYSE:BPMX) was the recipient of a significant decline in short interest in August. As of August 15th, there was short interest totalling 4,435,059 shares, a decline of 7.4% from the July 31st total of 4,790,336 shares. Approximately 7.7% of the company’s shares are sold short. Based on an average daily trading volume, of 830,191 shares, the short-interest ratio is presently 5.3 days.

Separately, ValuEngine raised shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 24th.

Biopharmx Corp (NYSE BPMX) opened at 0.2875 on Friday. Biopharmx Corp has a 12 month low of $0.19 and a 12 month high of $0.90. The firm’s 50-day moving average is $0.36 and its 200-day moving average is $0.49. The firm’s market capitalization is $21.31 million.

COPYRIGHT VIOLATION NOTICE: “Biopharmx Corp (BPMX) Short Interest Update” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/25/biopharmx-corp-bpmx-short-interest-update.html.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.